Refractory Takayasu arteritis successfully treated with infliximab.

Area of Science:

• Immunology
• Rheumatology
• Vascular Medicine

Background:

• Takayasu arteritis (TA) is a large vessel vasculitis characterized by chronic inflammation, leading to stenosis or aneurysms.
• Elevated proinflammatory cytokines, particularly tumor necrosis factor-alpha (TNF-alpha), are implicated in TA pathogenesis.
• Conventional treatments often fail to achieve clinical remission in TA patients.

Observation:

• A patient with Takayasu arteritis demonstrated resistance to conventional therapeutic approaches.
• Infliximab, a monoclonal antibody targeting TNF-alpha, was administered to the refractory patient.
• The patient experienced a clinical remission of Takayasu arteritis following infliximab treatment.

Findings:

• Infliximab effectively neutralized TNF-alpha, a key inflammatory mediator in TA.
• Successful clinical remission was achieved in a patient with treatment-resistant Takayasu arteritis.
• This case highlights the therapeutic potential of anti-TNF-alpha agents in refractory TA.

Implications:

• Infliximab represents a promising therapeutic option for Takayasu arteritis patients refractory to conventional therapy.
• Targeting TNF-alpha may be a viable strategy for managing severe or treatment-resistant TA.
• Further research is warranted to confirm the efficacy and safety of infliximab in a broader TA population.